Biotech Values

[DewDiligence]

DBTX IPOs 8.12M* shares @$18.00:

https://www.globenewswire.com/news-release/2021/02/12/2174646/0/en/Decibel-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine.

Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders.

A breakthrough in reversing acquired hearing loss would be quite an achievement.

*Assuming exercise of underwriter’s option.